The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2026 | BRCA testing in metastatic pancreatic cancer: guidelines and treatment implications
Teresa Macarulla, MD, Vall d’Hebron University Hospital, Barcelona, Spain, discusses the current understanding of DNA damage repair deficiencies in pancreatic cancer, and how genomic profiling is changing the approach to identifying and treating this molecularly defined subset of patients, especially as a result of the findings of the POLO trial (NCT02184195). This interview took place at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
